Podcasts about SG

How do you keep growing fast without breaking your business?In this Owned and Operated supercut, John Wilson pulls together his favorite moments from recent conversations on what actually snaps when you scale: cash, leadership bandwidth, and the frontline experience that drives revenue.You'll hear why growth is expensive (in trucks, infrastructure, and overhead), how disciplined operators reinvest instead of upgrading their lifestyle too early, and why “the war is won inside the home” no matter how good your dashboards look.If you're running HVAC, plumbing, electrical, or roofing and feeling the strain of growth, this episode gives you the frameworks—and the hard truths—to keep momentum without chaos.In this episode, you'll learn:Why growth consumes cash (and how to plan for it)The “overhead body” you must build early: leadership, CX, SG&A, marketing, purchasingHow owners stall out by pulling cash too early (the lifestyle trap)Why playbooks beat ego: don't reinvent the wheel (Nexstar and more)Why frontline obsession matters more than dashboardsHow onboarding + clear pay plans create a culture that performsConnect: John Wilson: https://x.com/WilsonCompanies

242 - Axel Ellis (the Runarounds, Ax and the Hatchetmen) In episode 242 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with Axel Ellis guitarist for the band/Amazon Prime Show “the Runarounds” and his band “Ax and the Hatchetmen”. In their conversation Axel gives us a little history of the band, a band that was cast for the Amazon show. Initially auditioning with his whole band for what they thought was a guest spot on an established show. Axel takes us through his musical history growing up in the suburbs of Chicago with parents that loved music and initially studying flamenco guitar before moving on to jazz and then rock. Axel describes how the show's characters mirrors his own start in music. Axel tells us about the benefits of being on a tv show, not just the fame and money, but the sponsorships from gear companies. Axel talks about his gear both for the Runarounds tv show, the bands tour that he's on now and for his other band “Ax and the Hatchetmen” Axel discusses the logistics for the band as far as being spread apart around the country for songwriting and rehearsals. Axel gives us his thoughts on his future of his band, the Runarounds band and the tv show's potential second season. To find out more about Axel you can go to his band website: axandthehatchetmen.com or the website for the Runarounds: therunarounds.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #AxelEllis #theRunarounds #AmazonPrimetheRunarounds #AxandtheHatchetmen #GretschGuitars #WhiteFalcon #SuproAmps #JamesPatrickRegan #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

In today's episode of Motley Fool Money, host Emily Flippen is joined by analysts Jason Hall and Asit Sharma to dive into three recent stories where the operating system underneath a business has started to matter more than the companies above it. They discuss: - Nvidia's $2 billion investment into CoreWeave and how AI infrastructure is colliding with physical constraints - How restaurant tech is pushing the limits on throughput - A rare-earth deal between private companies and the U.S. government highlighting what are issues of national security Companies discussed: NVDA, CRWV, TOST, SHOP, CAVA, SG, WING, USAR Host: Emily Flippen, Jason Hall, Asit Sharma Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

It's telling to hear NATO's future is not “guaranteed” according to a former NATO boss. After a jaw-dropping US threat to take Greenland shocked the world. President Trump's first year back in power is also overshadowing the United Nations' 80th milestone. Prompting calls to retool the world's top diplomat.  In this episode of Disorder, hosted by Mark Lobel, the former head of NATO tells Disorder we should make the United Nations Secretary-General the "chairman" of the Security Council. Brazil's former Ambassador to the United Nations says the role should be a single mandate term of six or seven years, "to retain the willingness to displease certain sources of power”. Recorded at a special UNA-UK event, George Robertson and Ambassador Antonio Patriota reveal how Donald Trump's disorderly approach is causing a major re-think of organisations and leadership in the world. Speaking in the same building that ushered in the United Nations General Assembly in 1946, exactly 80 years ago this month.  The Brazilian Ambassador to the UK didn't hold back ...  On Venezuela:  “I feel very uncomfortable as a South American to witness an intervention that is a flagrant violation of international law.”  On Nigel Farage joining climate talks:  “I don't think (he's) very eager to engage on this topic”  On presenting the Nobel Peace Prize to Trump:  “As a South American, I felt embarrassed by this gesture, because I don't think it enhances anybody's dignity to do that.”  Plus - George Robertson tips a British politician as the next big thing ... and it's not who you expect! Stay news of a special live event with Disorder and the UNA-UK for mega orderers, and to join our Mega Orderers Club and come along, and get ad-free listening, early release episodes, and bonus content, visit https://disorder.supportingcast.fm/  Producer: George McDonagh Subscribe to our Substack - https://natoandtheged.substack.com/ Disorder on YouTube - https://www.youtube.com/@DisorderShow Show Notes Links: You can get in touch with Mark, to host or speak at your event here: ⁠https://www.mark-lobel.com/getintouch⁠  To join our Mega Orderers Club in honour of Greg, for ad free listening and early release episodes, visit https://disorder.supportingcast.fm/ UNA UK website www.una.org.uk UN official article summarising the event - https://news.un.org/en/story/2026/01/1166783 Gordon Brown's call to action for democracies to reinvigorate the international order, highlighting the Attorney General's speech at the event - https://www.theguardian.com/commentisfree/2026/jan/20/donald-trump-greenland-world-plan-leadership Devex video interviews on Insta - https://news.un.org/en/story/2026/01/1166783 Sky News - 'Is the US attacking the UN's principles?' (Interview with the President of the General Assembly) https://news.sky.com/video/is-the-us-attacking-the-uns-principles-13495782  The Guardian - 'Guterres warns of ‘powerful forces' undermining ‘global cooperation.'' https://www.theguardian.com/world/2026/jan/17/antonio-guterres-warns-forces-undermining-global-cooperation-un-80th-anniversary-secretary-general-multilateralism-international-law  NPR - 'United Nations leaders bemoan global turmoil as the General Assembly turns 80.' https://www.npr.org/2026/01/18/nx-s1-5678366/united-nations-general-assembly-80-london#:~:text=LONDON — Just over 80 years,the importance of international cooperation.  Full speech by SG: https://webtv.un.org/en/asset/k1u/k1uo45t198 Learn more about your ad choices. Visit megaphone.fm/adchoices

What do Inception, Tim Robinson, Luis Buñuel, Woody Allen, and Chantal Akerman have in common? They all get compared to Hong Sang-soo's On the Beach at Night Alone in this episode of Deep Cut! Listen on as we unpack the movie that's loosely about Hong's and Kim Min-hee's career-changing relationship, digest more awkward dinner scenes, and discuss the merits of going to the beach in the winter.Links:Scold your friends for being inauthentic at our FREE patreon, discord server, and our socials @ www.deepcutpod.com Timestamps:00:00 Intro02:31 General reactions08:00 Context / Hong+Kim relationship14:32 SG public opinion survey18:04 Hong Sang-soo's 'Inception'20:08 Hong Sang-soo / Tim Robinson21:43 Hong / Buñuel25:45 Hong not planning era27:17 Ryan Swen Notarized and dinner scene33:16 What to do with this movie?38:13 Hong's Chantal Akerman41:10 Hong as Woody Allen

Yoo people in this weeks episode we have our bro on SG! We talk about what kind of parents we want to be, how we are planning to raise young black sons and SG talks us through how to rose to be senior footballing scout in the UK. We hope the Triple B Dry Jan Fast is going well. We're nearly at the end now, so let's keep pushing, keep sending in your videos, pictures, and messages, and let's finish strong! As always, any dilemmas or testimonies please send through !

What does real faith look like under fire? Jeff Haecker, Lisa Jones, and Victor Lams unpack sacrifice, belief, and resistance as SG-1 tests dangerous tech, Vala challenges false gods, and the Ori reveal their true nature. The post Line in the Sand (SG1) appeared first on StarQuest Media.

Fast casual restaurant stocks were hit hard over the past year, but many have snapped back over the past month. In today's episode of Motley Fool Money, Emily Flippen is joined by Fool analysts Sanmeet Deo and Jason Hall to break down what has caused the rebound, how consumer tastes have changed, and if fast casual stocks are set up for continued strong performance in the year ahead. Companies discussed: CAVA, CMG, SG, WING, EAT, SBUX, MAMA, JBFCF, YUM Host: Emily Flippen, Sanmeet Deo, Jason Hall Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

241 - Boy Golden In episode 241 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with singer/songwriter and producer Boy Golden aka Liam Duncan. In their conversation Liam describes his upcoming tour schedule in Canada and growing up in rural Manitoba in the cold. Liam talks gear, his guitars and amps and his collection of Russian microphones and a special guitar labeled Garnet after the amp maker. Liam tells us about his earlier band “the Middle Coast” before he went out as Boy Golden and he explains the Boy Golden moniker. Liam talks about his time as the keyboardist for the Bros. Landreth and his influences early on. Liam discusses his new album “Best of Our Possible Lives” and the personal on the album and he also describes his home studio. To find out more about Boy Golden you can go to his website: boygolden.ca Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #BoyGolden #theMiddleCoast #LiamDuncan #Manitoba #theBrosLandreth #YamahaGuitars #JamesPatrickRegan #BestofOurPossibleLives #theDeadlies #HomeStudio #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

In most companies, budget season is a predictable exercise in "incrementalism," taking last year's numbers and adding a 5% bump. But what happens when leadership drops a bomb and says, "This year, we start from zero"?In this episode of Corporate Finance Explained on FinPod, we explore Zero-Based Budgeting (ZBB), a high-stakes financial framework in which every dollar must earn its right to exist. We unpack the mechanics of ZBB, the "Save to Grow" mindset, and the cautionary tales of companies that saved themselves into obsolescence.ZBB vs. Traditional Budgeting: The Logic FlipThe fundamental difference between ZBB and the status quo is a shift in perspective:Traditional Budgeting: Asks, "How much more or less do we need than last year?" It is comfortable, based on precedent, and often hides "historical entitlement."Zero-Based Budgeting: Asks, "If we were building this function from scratch today, what would we actually fund?" It treats every expense as discretionary and requires a strategic justification for every line item.The Mechanics: Decision Packages and Tiered FundingThe core engine of a successful ZBB program is the Decision Package. Rather than funding a department, leadership funds specific activities using a three-tiered approach:Minimum Level: The "keep the lights on" spend. The bare minimum required for operations and regulatory compliance. Current Level: Business-as-usual spending. Enhanced Level: Discretionary funding for innovation, R&D, and new customer acquisition.This framework allows leadership to make strategic trade-offs. For example, funding a "minimum" level for administration to prioritize "enhanced" funding for revenue-driving marketing.Case Studies: The Scalpel vs. The AxeKraft Heinz (The Warning): Following a 2015 merger, the company applied a "ruthless" ZBB model. While margins shot up instantly, they cut too deeply into R&D and brand-building. The result was massive brand erosion and billions in write-downs. Unilever (The Blueprint): In response to market pressure, Unilever adopted a "Save to Grow" ZBB model. They targeted specific SG&A categories but "ring-fenced" strategic areas like innovation. Savings were immediately reinvested in the business, proving that ZBB can be a tool for growth, not just austerity.The Role of FP&A: From Scorekeeper to ArchitectWithout a strong Financial Planning & Analysis (FP&A) team, ZBB is just a spreadsheet exercise. In a ZBB environment, FP&A professionals must:Define Cost Drivers: Moving away from "last year's bill" to metrics like transaction volume or headcount.Assign Ownership: Ensuring the person who owns the activity is the one defending the spend.Differentiate Costs: Protecting "Change the Business" costs (future investments) from being swallowed by "Run the Business" costs (daily operations).

This Sunday school lesson talks about the power of bold and humble prayers. What I keyed in on was how Abraham used that power. Genesis 18:16-25 God has a role for Abraham and his family to play in his plan—a ministry. This is the first time he brings him into it. S&G are unjust and cruel. Abraham advocates…

Tales of Three Campaign OneArc 2.1: OladellEpisode 69: A Gift and a Departure Join us as we say goodbye to Oladell! Our trio accept a gift from Velrith and head off on their next adventure.Content Warnings: Reference to alcohol consumption and being drunk, and Profanity Tales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy!Follow the Cast:Arianna as Elara SpinelsparkDusty as Ivy Nightbreeze-TinkerfeyWayra as VéresFind our socials here!Want to chat with the cast, talk spoilers, play games, and make new friends? Join our Discord!If you want to help keep the podcast running and get access to bonus content check out our Patreon or buy us a coffee on Ko-fi!Special thanks to SG for theme song, Chriss for the logo, Fenn & Ely for the character art!Background music and SFX by Epidemic Sounds & Monument Studios.This week we're featuring our friends at Somebody's Heroes Podcast. Check out their podcast here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

240 - Joel Hoekstra In episode 240 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with guitarist Joel Hoekstra, in their conversation Joel describes living in New York City and growing up in the suburbs of Chicago with his parents who were both classical musicians and Joel tells us why he didn't pursue piano. Joel describes the impact of seeing AC/DC on MTV as a kid which slowed his sports interests. Joel describes his gear starting on his stepmom's guitar and he discusses his guitars from then on… and how he got the collecting bug and he discusses his custom Gibson's and Jackson's and the guitars he uses for each of his gigs. Joel tells us about his first bands through his gigs with Trans Siberian Orchestra, Whitesnake, Night Ranger, Jim Peterik, Cher… as well as his time spent as a pit guitarist for Broadway shows like Rock of Ages and Love Janis. Joel talks about using in-ear monitors and hearing loss and Joel talks about his time at GIT in Hollywood and working at Cherokee Studios. Joel discusses his new album “From the Fade” and the personal on the album and the chances for a tour and he describes the other projects he's working on: Revolution Saints, Hoekstra Gives, teaching remote lessons, Broadway's Rock of Ages band and Iconic (which includes a lot of his former Whitesnake bandmates as well as time spent producing other artists. Finally Joel tells us about what he does when he's not playing guitar… his kids, and anything to escape music and plans to go to NAMM next week. To find out more about Joel you can go to his website: joelhoekstra.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #JoelHoekstra #Whitesnake #TransSiberianOrchestra #JacksonGuitars #GibsonCustomShop #JamesPatrickRegan #FromtheFade #theDeadlies #NightRanger #RockofAges #Hoekstra13#haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

Season 6 Episode 21: Prophecy Jonas Quinn aka Corin Nemec tries to impress the Gang one final time by developing PreCog Abilities that can save them from certain disaster.  As they're trying to figure the situation on a super poor planet with bad food but some decent Naquadah reserves, the Gang decide to forget about the last six season, and just not listen to the man.   Teal'c, you forget about the invisible bugs episode!?  CARTER, YOU WERE A FREAKIN GOTHIC COMPUTER AI!!  But precog abilities?  Impossible!   Daddy Hammond finally believes him, and through some weird machinations of quantum mechanics, his future predictions don't come true, and the mountain base and the poor planet are saved.  Unfortunately, we can't say the same for the character of Jonas, and Corin Nemec's future with SG-1.   It sucks.   ----more---- 00:00 - Intro 6:08 - 24 Seconds 7:53 - Episode Debrief 1:09:03 - Were We Comforted 1:10:50 - Yeh Neh or Meh 1:14:00 - Next Episode 1:16:13 - ComeTrya! 1:17:25 - Get To Know Your Hosts 1:19:36 - Outro  

Shoot us a Text.Episode #1241: CarMax leans on price cuts and marketing to spark sales, Toyota takes its iconic Hilux electric in Europe, and Walmart keeps scaling drone delivery as demand grows.CarMax is shifting back to fundamentals as sales and earnings continue to slide. The company will cut prices, trim costs, and increase marketing to regain momentum heading into 2026.Q3 results saw unit sales down 8% and earnings down 50% year-over-year.CarMax will use targeted price cuts to spark demand, not blanket reductions.The company is lowering margins while boosting marketing to drive traffic.SG&A will be cut by $150M annually despite increased ad spend.“Our average selling prices have drifted upward and appear to be less attractive to customers,” said Interim CEO David McCreight.Toyota just electrified one of its most important global trucks. The Hilux made its first European appearance as a full EV, signaling Toyota's pickup electrification push—just not for North American buyers.Toyota debuted the Hilux BEV at the Brussels Motor Show, and uses a 59.2 kWh battery, offering up to 160 miles WLTP range, or 236 miles in city driving.With AWD and 473 Nm of torque, it can tow 1.6 tons and haul over 1,500 lbs, keeping its work-truck credibility.Europe gets the Hilux BEV in April, but the truck isn't sold in the U.S.—and Toyota isn't signaling that will change.Alphabet-owned Wing is dramatically expanding its on-demand drone partnership with Walmart, signaling that flying groceries and meds are becoming a real part of everyday commerce.Wing will expand drone delivery to 150 more Walmart stores, building on pilots in Dallas-Fort Worth and Atlanta.Wing's top 25% of customers order three times per week, mostly groceries like eggs, ground beef, produce, and snacks.Once complete, Wing will operate from 270+ Walmart locations, reaching roughly 10% of the U.S. population.Walmart remains Wing's primary commercial partner, even as the company continues testing larger drones capable of carrying five-pound payloads.Wing's new chief business officer Heather Rivera: “Volume is definitely powering our flywheel.”Join Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/

Can virtue defeat gods? SG-1's hunt for the Sangraal pits faith against force, while Ba'al and Adria turn allies into liabilities. Lisa Jones, Jeff Haecker, and Victor Lams weigh the cost of power—and Daniel's fate. The post The Quest (SG1) appeared first on StarQuest Media.

Steiny & Guru wonder what the fans will be feeling on Monday in the event of a loss, tight game, win... What is the headline when you wake up next time for S&G?

Tales of Three Campaign OneArc 2.1: OladellEpisode 67: Tuning Fork to the CityIt's party time! After all their hard work, our trio gets to relax, have one too many drinks, and play some games! Ivy and Rayla get closer, Novick has a heart to heart with Elara, and Véres makes plans to meet up with Jerek for a night cap.Content Warnings: Complicated Relationships, Profanity, Dating, Romance and Sexual SituationsTales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy!Follow the Cast:Arianna as Elara SpinelsparkDusty as Ivy Nightbreeze-TinkerfeyWayra as VéresFind our socials here!Want to chat with the cast, talk spoilers, play games, and make new friends? Join our Discord!If you want to help keep the podcast running and get access to bonus content check out our Patreon or buy us a coffee on Ko-fi!Special thanks to SG for theme song, Chriss for the logo, Fenn & Ely for the character art!Background music and SFX by Epidemic Sounds & Monument Studios.This week we're featuring our friends at Somebody's Heroes Podcast. Check out their podcast here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Tales of Three Campaign OneArc 2.1: Oladell Episode 67: Tuning Fork to the CityAfter their success of fixing the dam, TUO is honored by the town with a ceremony, given gifts, and has a celebration thrown in their name! Content Warnings: Anxiety, Emotional Distress, Profanity, and Romantic and Sexual Situations Tales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy! Follow the Cast:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Arianna⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠as Elara Spinelspark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dusty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as Ivy Nightbreeze- Tinkerfey  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wayra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as Véres Find our socials ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  Want to chat with the cast, talk spoilers, play games, and make new friends? Join our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  If you want to help keep the podcast running and get access to bonus content check out our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!Buy us a coffee on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ko-fi⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Special thanks to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SG ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the theme music, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chriss ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the logo, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fenn ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ely ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the character art! Background music and SFX by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Epidemic Sounds⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Monument Studios⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This week we're featuring our friends at Somebody's Heroes Podcast. Check out their podcast here!

Winter Total Request Live 2026 begins as Tread Perilously watches an episode of Stargate SG-1 called "Thor's Chariot." When the SG-1 team receives a distress signal from Cimmeria, they return to the planet finding a Goa'uld invasion and few Cimmerians left to fight. While O'Neil and Teal'c scout out the enemy encampment, Daniel and Sam learn the secret of Thor's might. Will it be enough to defeat the Goa'uld known as Heru'ur? Will anyone be able to pronounce their new adversary's name? And will Thor prove to be as real as Ra or his son? Erik and Justin discuss their histories with Stargate and SG-1. Erik makes a surprising proclamation about the work of director Roland Emmerich. Stan Lee proves to be more formidable than any Gou'ald. Pronunciations of Stargate names come into question, as does the choice to name the planet "Cimmeria". The SG-1 cast -- which includes Michael Shanks, Amanda Tapping, Christopher Judge, and Don S. Davis -- gets their flowers even if Erik has a small problem with Richard Dean Anderson playing Col. Jack O'Neil. Erik doubts Beth Grant's dedication to Sparkle Motion. The Ancient Astronaut Theory proves to be an obstacle in enjoying any Stargate. The pair once again advocate for cheaper-looking sci-fi television and Erik announces a change to the Patreon.

What happens when SG-1 wins through deception instead of firepower? Jeff Haecker, Lisa Jones, and Victor Lams break down a space-bound thriller full of cons, double-crosses, and Vala's street smarts—plus why “Company of Thieves” quietly highlights the team's versatility. The post Company of Thieves (SG1) appeared first on StarQuest Media.

Shoot us a Text.Why Dealers Will Win, Frozen Waymos, Gen Z Loves Holiday ShoppingDescription:Episode #1225: Cars Commerce's Alex breaks down why the future isn't car vending machines, Waymo robotaxis freeze during a San Francisco power outage, and Gen Z embraces the holiday experiences.SPONSOR READ:There will always be that customer who calls at 11:47 PM asking if the blue Tahoe is still available.Before Mia? That call went poof. Lost to the universe. And that customer? Who knows?Mia answers that customer at 11:47 pm, instantly and cheerfully. She books the appointment, checks inventory, sends the details, and suddenly that late-night caller becomes taillights over the curbShe's handled over a million customer calls to date and created millions in incremental revenue.Don't leave your late night callers hanging, give Mia a call. AnnouncementNext weeks 2026 Strategy Sessions12/26 Brian Benstock12/29 12/30 Brian Kramer12/31 Steve Greenfield1/1 2025 In Review1/2 Damon LesterUpcoming ASOTU Edge Webinar on January 7th at 2PM - AI That Works as Hard as You Do: Practical Tips for Faster Sales with Danny Veliz and Sarah HicksInterview with Cars Commerce CEO Alex Vetter - Show Notes with links:In a reflective interview, Cars Commerce leader Alex encourages dealers to use better tech to get leaner, faster, and more customer-friendly. Alex says the next wave of dealership tech has to reduce SG&A and improve operational efficiency, not just add more dashboards.He calls out a stubborn reality: sales per salesperson hasn't improved in about a decade, even as tools multiplied — and says AI should finally change that.He pushes back on the “dealers hate change” narrative, arguing dealers are highly adaptable entrepreneurs who will adopt what actually helps them win.The consumer journey gets more complicated closer to purchase, with more indecision around vehicle feel, color, space, and drive — meaning the funnel “widens” at the end.His bottom line: the winning model is omnichannel that finishes with a strong local dealer, saying, “I don't think the consumer wants a vending machine… they want an online experience that finishes with a local partner.”Waymo's driverless ride service ran into a very human problem this weekend: no power. A widespread outage across San Francisco left robotaxis frozen mid-ride, snarling traffic and raising fresh questions about how autonomous vehicles handle chaotic, real-world conditions.A power outage knocked out traffic lights across San Francisco, with social media videos showing mJoin Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/

239 - Tom Paxton and John McCutcheon239 - Tom Paxton and John McCutcheon In episode 239 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with singer/songwriters and guitarists Tom Paxton and John McCutcheon who is also a multi-instrumentalist. He first spoke to John in episode 150. In their conversation he starts with Tom and he tells us about his home in Alexandria, VA, right across the river from Washington, DC and he tells us about starting on trumpet before starting on guitar as a senior in high school. The two tells us about when they first met in Boston in the early '80's and how they came together as songwriting partners during Covid. John describes recording their album “Together Again” in the same room with the exception of Stuart Duncan on fiddle. “Together Again” being their second collaboration after their first “Together”. John discusses his instruments on the album an Ome banjo and Huss and Dalton guitars and Tom tells us about his Martin M-38 he has at home. Tom talks about why he retired from touring and John tells us about his upcoming tour plans and the two tell us about their writing projects. The two discuss their holiday traditions, Tom renting a Virginia ski cabin and John with a huge Cuban Christmas Eve feast and the two have a traditional of writing unconventional Christmas songs. You can find out all you want to know about John at his website: folkmusic.com and for more information on Tom you can go to his website at: tompaxton.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #JohnMcCutcheon #TomPaxton #TogetherAgain #HussandDalton #stuartduncan #FolkMusic #MartinGuitar #OMEBanjos #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

In this episode of Owned and Operated, John Wilson and Jack break down what “smart investing” actually looks like for home service operators—starting with the truth most owners miss: if you run a business, you're already an investor. You're investing money, attention, and people every day.They start with a practical framework for P&L investing (software, headcount, SG&A): if your business sells for a multiple, then any new expense should produce a return that justifies that multiple—otherwise, you may be quietly reducing enterprise value.From there, they unpack the difference between balance sheet investments (trucks, equipment, inventory) vs P&L investments, why banks and buyers mostly care about EBITDA, and how focusing on fewer initiatives can drive more profitable growth.Then they shift into the “outside the business” conversation: when diversification helps, when it's a distraction, and how operators can think in two buckets—cash-flow assets that fund life, and enterprise-value assets that build wealth.If you're adding software, hiring leaders, buying equipment, or debating real estate vs reinvesting in the core business—this episode gives you a clean way to think about ROI, focus, and capital allocation.What You'll LearnWhy every operator is an investor (capital, people, and attention allocation)A simple rule for P&L expenses: should this generate a 3x+ return based on your business multiple?The difference between investing on the balance sheet vs the P&L

238 - Jeremy Pinnell In episode 238 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with singer, guitarist and songwriter Jeremy Pinnell. In their conversation Jeremy discusses his home in Southgate, Kentucky and his son, who's 11. Jeremy tells us about starting guitar at 13 and watching his dad in the church band while he was a kid and not being able to listen to secular music and his first musical purchase being the Sex Pistols album. Jeremy describes starting on his dad's Ovation guitar eventually getting a Cort guitar and Gorrilla amp before getting a Fender Paisley Strat and he tells us of his love of Telecasters and using .13 gauge strings and his Harmony that he bought from JD Simo. Jeremy discusses his tour schedule playing both solo and with a band. Jeremy tells us how he got hooked up with Shooter Jennings who produced Jeremy's most recent album “Decades”. Finally Jeremy describes what he does for fun: Ju Jitsu and Kick boxing and Jeremy tells us about his Christmas traditions. To find out more about Jeremy you can go to his website: jeremypinnell.com Please subscribe, like, comment, share and review this podcast! #JeremyPinnell #ShooterJennings #Decades #VintageGuitarMagazine #JDSimo #HarmonyGuitars #FenderTelecaster #JamesPatrickRegan #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

Which means of various green transportation can decarbonise the most? Synopsis: Every 3rd Wednesday of the month, The Straits Times examines not just vehicle prices but wider transport issues and trends connected to public and private transport. From October 2026, travellers departing Singapore will contribute to the purchase of Sustainable Aviation Fuel (SAF). But is this levy enough to tackle aviation’s carbon problem? Hosted by ST senior transport correspondent Lee Nian Tjoe, the panel - comprising Mr Andrey Berdichevskiy, partner and associate director of Boston Consulting Group and Professor S. Viswanathan from Nanyang Business School - discusses the hard-to-abate aviation sector, the true cost of green flying, and whether we should rethink that long-haul trip to visit the northern lights. Back on the ground, the conversation shifts to the return of the Robo-taxi. Are autonomous vehicles the solution to our “last mile” woes in estates like Punggol? Plus, the experts share practical advice on the “Avoid, Shift, Improve” framework, from taking the train to KL, to swapping a steak for a salad in helping commuters to keep it “wheel and green”. This episode was recorded and filmed on Dec 2 at SPH Media’s revamped auditorium, in front of a live audience of 60 ST readers. It was the sixth and final ST Podcast Live! Session for 2025, capping a special series celebrating The Straits Times’ 180th anniversary. Highlights (click/tap above): 01:43 The cost of greening skies in Sustainable Aviation Fuel (SAF) and for flights out of SG 04:45 Why increasing ticket prices doesn’t dampen travelling 12:09 A practical framework for greener mobility choices, from Zoom calls to high-speed rail 19:47 The return of autonomous vehicles like the Robo-taxi 31:38 From giving up the car to adopting a "flexitarian" diet - what else can individuals? Read Lee Nian Tjoe's articles: https://str.sg/wt8G Follow Lee Nian Tjoe on LinkedIn: https://str.sg/iqkJ Read more COE articles: https://str.sg/iGKC Host: Lee Nian Tjoe (niantjoel@sph.com.sg) Produced & edited by: Eden Soh Executive producers: Ernest Luis and Lynda Hong Follow Wheel Insights Podcast here and get notified for new episode drops: Channel: https://str.sg/iTtE Apple Podcasts: https://str.sg/iqW2 Spotify: https://str.sg/iqgB Feedback to: podcast@sph.com.sg SPH Awedio app: https://www.awedio.sg --- Follow more ST podcast channels: All-in-one ST Podcasts channel: https://str.sg/wvz7 Get more updates: http://str.sg/stpodcasts The Usual Place Podcast YouTube: https://str.sg/4Vwsa --- Get The Straits Times app, which has a dedicated podcast player section: The App Store: https://str.sg/icyB Google Play: https://str.sg/icyX --- #wheelinsightsSee omnystudio.com/listener for privacy information.

237 - Ward Davis In episode 237 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with singer, songwriter and guitarist Ward Davis. In their conversation Ward discusses where he currently lives, Hartsville Tennessee and where he grew up Arkansas and starting on the piano at 6 years old and moving to guitar at 14 after losing at the county fair talent show to a guitar player and then started playing jamborees around the area he lived in. Ward tells us about the shows he's doing now supporting Cody Jinks with his band and his own shows. Ward tells us about his guitars, Larrivee's outfitted with either Fishman or L.R. Baggs pickups and he discusses his telecaster's built by 9 Point Guitars in Louisiana. Ward discusses how he got hooked up with Cody Jinks in the first place and how he got his songs in front of Willie Nelson and Merle Haggard and gives us a lesson in the economics of songwriting. Ward talks about using an alias (Dusty Manchester) at writers rounds to avoid the radius clause. Ward tells us about his new album “Here I Am” which comes out in February and he tells us about working with Brent Mason, Eddie Bayers among others and landing tracks on the Landman TV series. Ward describes why he chose to be on a label as opposed to releasing his album independently. Ward discusses his upcoming tour schedule after the holidays. Finally Ward tells us about collecting historical documents and books from the 1800's and his love of thrift stores and his relationships and sobriety. To find out more about Ward you can go to his website: warddavismusic.com Please subscribe, like, comment, share and review this podcast! #WardDavis #CodyJinks #HereIAm #VintageGuitarMagazine #Landman #DustyManchester #LarriveeGuitars #9PointsGuitars#lrbaggs #JamesPatrickRegan #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

236 - the Protomen (Raul Panther III and Shock Magnum) In episode 236 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with Raul Panther III and Shock Magnum from the Protomen. In their conversation the two tell us about their history with band which has been around since 2005 and has quite the ravenous fan base. Both Raul and Shock tell us about their roles in the band both playing guitar and Raul singing lead and playing keyboards as well. They both talk about their base which is Nashville and where the grew up and Raul tells us about singing at an early age backing John Denver and Shock tells us about learning guitar from his brother. Raul takes us through the history of the band which started as a project from fellow MTSU students and the two tell us about their songs that have been used in tv shows and commercials and they talk about what venues they usually play. Raul and Shock discuss the Protomen's new album “Act III: This City Made Us” and they talk gear: Shock's Gibson's and Orange amps and Raul's Tom Anderson Raven through a Kemper profiler. The two tell us about what they do outside of music: family and working in the garage. To find out more about the Protomen you can go to their website: protomen.com Please subscribe, like, comment, share and review this podcast! #theProtomen #RaulPantherIII #ShockMagnum #ActIIIThisCityMadeUs #VintageGuitarMagazine #TomAndersonGuitars #GibsonGuitar #OrangeAmps #JamesPatrickRegan #KemperProfiler #MTSU #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

Tales of Three Campaign OneArc 2.1 OladellEpisode 65: Ghosts and Grim ReapersWith some help from the town, our trio finally gets the piericor out of the dam and riding the high of their success they rush off to work on fixing the structural damage. While Véres and Velrith put the gears back in place, Elara tries to get others to see the vision she saw of Lyca, which results in Ivy seeing some ghosts. Content Warnings: Deep Water, Emotional Distress, Fantasy Violence, Gore, and ProfanityTales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy! Follow the Cast:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Arianna⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠as Elara Spinelspark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dusty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as Ivy Nightbreeze- Tinkerfey  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wayra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as Véres Find our socials ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  Want to chat with the cast, talk spoilers, play games, and make new friends? Join our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  If you want to help keep the podcast running and get access to bonus content check out our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!Buy us a coffee on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ko-fi⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Special thanks to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SG ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the theme music, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chriss ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the logo, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fenn ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ely ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the character art! Background music and SFX by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Epidemic Sounds⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Monument Studios⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ This week we're featuring our friends at The Thornefiles Podcast. Check out their podcast ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠! 

www.linktr.ee/truthstreamhttps://rumble.com/user/QNewsPatriotLife Wave link https://liveyounger.com/truthstream

We are thrilled to welcome Brian Markinson to explore his role as the Enkaran Lotan from SG-1's "Scorched Earth" and spend time discussing his career!

235 - Old Crow Medicine Show (Ketch Secor and Mike Harris) In episode 235 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host, James Patrick Regan speaks with Ketch Secor and Mike Harris from the Old Crow Medicine Show about their new Christmas album “OCMS XMAS” and their Christmas tour that's happening now they also talk about a Christmas single they released a few years ago, the tour ends at the Ryman on New Year's Eve. James talked to Ketch in episode 197 about the history of the band. Mike tells us about his entrance in to the band and briefly describes his history before that and how a one off novelty act “the Anal Beatles” led to his introduction to Ketch. The two discuss what they do for Christmas which includes Christmas decorations hi powered egg nog and model trains. Mike and Ketch discuss their instruments for the album and tour and what they have at home as well and Ketch tells us about “junkin”, searching for treasures and old instruments while on tour and the two tell us where they get their instruments repaired. The two tell us about a couple of early Christmas memories they have which involve their grandfathers that they immortalized in a song called “Grandpa's Gone”. To find out more about Old Crow Medicine Show you can go to their website: crowmedicine.com Please subscribe, like, comment, share and review this podcast! #KetchSecor #OldCrowMedicineShow #OCMSXMAS #VintageGuitarMagazine #GrandpasGone #MartinGuitars #ChristmasAlbum #JamesPatrickRegan #MikeHarris #AnalBeatles #theDeadlies #haveguitarwilltravelpodcast #HGWT #TourLife Please like, comment, and share this podcast! Download Link

Hey YC Online! Sermon notes: https://static1.squarespace.com/static/592f36b4d1758e4fdf70080e/t/693208a22a6c9b6d0739a454/1764886690647/SG+12_06_25+ADVENT+%232+Week+2.pdf ABOUT YOSEMITE CHURCH: Our mission is meeting people where they are and loving them to where Christ wants them to be. Yosemite Church wants to help you find your next step. Find locations, videos, and more info about us at https://yc.church/ or download the Yosemite Church app. NEXT STEPS: Have you made a decision to follow Jesus? You may be wondering what's next on your journey. We want to help! Let us guide you to your next steps in your walk with Christ: https://yc.church/baptism GIVE ONLINE: https://pushpay.com/g/yosemitechurch FIND US ON SOCIAL MEDIA: https://www.facebook.com/yosemitechurch https://www.instagram.com/yosemitechurch/ All music performed under CCLI Licenses: 6010 and CSPL028666

Featuring an interview with Dr Priyanka Sharma, including the following topics: Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00) Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13. Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25) Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;Abstract 292MO.  Efficacy and safety findings with TROP2-directed antibody-drug conjugates for metastatic TNBC (5:11) Cortés JC et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). ESMO 2025;Abstract LBA20.  de Azambuja E et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. ESMO 2025;Abstract LBA22.  Dent R et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. ESMO 2025;Abstract LBA21.  CME information and select publications

Massenentlassungen, BIP-Rückgang und viel Unsicherheit: Die Schweizer Wirtschaft kämpft mit Problemen. Aus der Politik werden einerseits Forderungen nach einer Entlastung der Unternehmen laut. Andererseits kritisieren die Gewerkschaften die stagnierenden Löhne. Was ist zu tun? Die Schweizer Wirtschaft steht unter Druck. Die kürzlich publizierten Zahlen des Staatssekretariats für Wirtschaft (Seco) zeigen: Das Bruttoinlandprodukt ist im dritten Quartal 2025 um 0,5 Prozent gesunken. Gleichzeitig streichen grosse Firmen wie Novartis, Selecta oder Nestlé insgesamt mehrere hundert Stellen in der Schweiz. Was ist los mit der Schweizer Wirtschaft? Ist die Talsohle erreicht oder ist ein weiterer Rückgang der Wirtschaftsleistung zu befürchten? Und welche Rolle spielt dabei der Zollstreit mit den USA? Die Entwicklungen beeinflussen nicht nur die Arbeitslosenquote, sondern auch die Löhne. Der Gewerkschaftsbund fordert, dass es bei den Löhnen aufwärts geht. Der Arbeitgeberverband warnt: Es brauche Augenmass bei der Lohnrunde. Doch wie steht es tatsächlich um die Kaufkraft der Angestellten? Nimmt sie zu oder ab? Bund will Unternehmen entlasten Der Bundesrat hat vergangene Woche ein Paket von 28 Massnahmen verabschiedet, das zur regulatorischen Entlastung der Unternehmen führen soll. Zu den Massnahmen gehören unter anderem Entlastungen bei der Anmeldung von Kurzarbeit oder im Bereich der Mehrwertsteuer, der Verrechnungs- und der Stempelsteuer. Macht der Bund genug für die Unternehmen oder muss er die Bürokratie weiter abbauen? Und wie steht es um die Angestellten? Gemäss der Gesundheitsbefragung 2025 der CSS fühlen sich 69 Prozent der Befragten häufig erschöpft und müde. Muss die Politik Arbeitnehmende stärker schützen? Zu diesen Fragen begrüsst Sandro Brotz am 5. Dezember 2025 in der «Arena»: – Franziska Ryser, Nationalrätin Grüne/SG; – Benjamin Giezendanner, Nationalrat SVP/AG; – Daniel Lampart, Chefökonom Schweizerischer Gewerkschaftsbund; und – Stefan Brupbacher, Direktor Swissmem.

234 - Jake Shimabukuro (II) In episode 234 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host, James Patrick Regan speaks again with ukulele master Jake Shimabukuro. They spoke in the lobby of the hotel he was staying at, please excuse the noise. In their conversation Jake tells us about his new Christmas album with a lot of collaborations including Jimmy Buffet, Michael McDonald and Yo-Yo Ma to name a few and his holiday tour that's happening now. Jake talks about his childhood Christmas's in Hawaii and his relationship with ukulele builder Kamaka and Jake's signature ukulele. Jake describes his early influences including Herb Ohta Sr. and Eddie Kamae. Jake tells us about his singer and guitarist in the band Justin Kawika Young his longtime bassist, Jackson Waldhoff. Jake describes his relationship with other Hawaiian artists like Keola Beamer, John Keawe and Ledward Ka'apana to name a few. Jake discusses the business side of his career and tells us about his favorite Hawai'ian island. Jake talks about a couple projects he's working on for the future including a tribute album to George Harrison and his new love of slide ukulele. To find out more about Jake and his Christmas album and tour you can go to his website: jakeshimabukuro.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #JakeShimabukuro #Kamaka #TistheSeason #JimmyBuffet #JamesPatrickRegan #KamakaUkulele #YoYoMa #MichaelMcDonald #theDeadlies #ChristmasMusic #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

JakeDumpin is swaddling you with video game goodness, just let it happen. The Dumpster Boy guides us through episode 186 discussing Metroid Prime 4 Beyond, Geoff Keighley's secrets, and JakeTwitchin is going to guess where previous Game Awards winners landed on the Spotlight Games Top 100, as decided by you, the audience, 86 episodes ago.  Timecodes What we're playing - 3:50 Metroid Prime 4 Beyond review roundup - 12:35 Geoff Keighley has SECRETS - 23:00 JakeTwitchin guesses SG's Top 100 - 27:47 Follow us! www.dropindropoutpod.com Bluesky, YouTube, IG, Threads and TikTok @spotlightgamespod Twitch.tv/spotlightgamespod Join our discord! https://discord.gg/Vxvp2sX64Z Email the show: mail@spotlightgames.net RSS Feed: https://spotlightgames.libsyn.com/rss Spotlight Games Theme by Chike Okaro @bassicfun Thanks for listening!

Episode Summary: In this episode of the Solar Maverick Podcast, Benoy sits down with Rob Sternthal, Managing Director at Expedition Infrastructure Partners, to break down how investors evaluate solar platforms and development pipelines. Rob brings more than 20 years of experience in investment banking, tax equity, structured finance, and renewable energy, and he explains the real criteria that determine platform value today. Benoy and Rob discuss why platforms are being repriced, how rising SG&A and longer development timelines are reshaping exits, and what investors are prioritizing in the current market. They also cover the Pine Gate bankruptcy, the renewed shift toward “develop and flip,” battery economics, tax credit insurance constraints, FEOC uncertainty, and the wave of distress expected to define the industry over the next two to three years. Biographies Benoy Thanjan Benoy Thanjan is the Founder and CEO of Reneu Energy, solar developer and consulting firm, and a strategic advisor to multiple cleantech startups. Over his career, Benoy has developed over 100 MWs of solar projects across the U.S., helped launch the first residential solar tax equity funds at Tesla, and brokered $45 million in Renewable Energy Credits (“REC”) transactions. Prior to founding Reneu Energy, Benoy was the Environmental Commodities Trader in Tesla's Project Finance Group, where he managed one of the largest environmental commodities portfolios. He originated REC trades and co-developed a monetization and hedging strategy with senior leadership to enter the East Coast market. As Vice President at Vanguard Energy Partners, Benoy crafted project finance solutions for commercial-scale solar portfolios. His role at Ridgewood Renewable Power, a private equity fund with 125 MWs of U.S. renewable assets, involved evaluating investment opportunities and maximizing returns. He also played a key role in the sale of the firm's renewable portfolio. Earlier in his career, Benoy worked in Energy Structured Finance at Deloitte & Touche and Financial Advisory Services at Ernst & Young, following an internship on the trading floor at D.E. Shaw & Co., a multi billion dollar hedge fund. Benoy holds an MBA in Finance from Rutgers University and a BS in Finance and Economics from NYU Stern, where he was an Alumni Scholar. Rob Sternthal For the last 20+ years, Rob has been a leading investment banking executive and recognized platform builder across the renewable power, energy, ESG and real assets sectors, advising on more than $25 billion of transactions. Prior to joining XIP, Rob was a Managing Director focusing on renewable power at Piper Sandler. Before that, Rob was responsible for building platforms at Rubicon Capital Advisors as well as CohnReznick (now CRC-IB). He founded and built CohnReznick's Capital Markets group (CRC) into a market-leader over ten years, completing nearly $20 billion in transactions and managing a team of 30 professionals. Prior to CRC, Rob established and led multiple real estate and asset-backed securities practices for Credit Suisse in the United States as well as internationally. He began his career as an attorney for the U.S. Securities & Exchange Commission as well as in private practice at Milbank. Rob received a bachelor's degree in economics and French, with honors, from Emory University and a Juris Doctorate, cum laude, from the Temple University School of Law. Rob is a Registered Representative of BA Securities, LLC. Member FINRA, SIPC. Stay Connected: Benoy Thanjan Email: info@reneuenergy.com  LinkedIn: Benoy Thanjan Website: https://www.reneuenergy.com Website: https://www.solarmaverickpodcast.com   Rob Sternthal Linkedin: https://www.linkedin.com/in/robert-sternthal-548b287/    Website:  ​​https://xipllc.com/  Email:  Rob@xipllc.com  NPM Podcast related to XIP's partnership with Gordian:   https://newprojectmedia.com/npm-interconnections-us-episode-172-rob-sternthal-peter-kauffman-xip-gordian/  If you enjoyed this episode, please rate, review and share the Solar Maverick Podcast so more people can learn how to accelerate the clean energy transition.   Join Us for the Winter Solstice Fundraiser!  I'm excited to invite you to our Winter Solstice Fundraiser, hosted by Reneu Energy and the Solar Maverick Podcast on Thursday, December 4th from 6–10 PM at Hudson Hall in Jersey City, NJ! https://www.tickettailor.com/events/reneuenergy/1919391 This event brings together clean energy leaders, entrepreneurs, and friends to celebrate the season while raising funds for the Let's Share the Sun Foundation, which installs solar and storage systems for families and communities in need in Puerto Rico. We'll have: -Great food and drinks -Amazing networking with solar and sustainability professionals -Sports memorabilia auctions (with proceeds benefiting Let's Share the Sun) -An inspiring community focused on making an impact through solar energy If you or your company would like to get involved as a sponsor, please message us at info@reneuenergy.com.     Reneu Energy Reneu Energy provides expert consulting across solar and storage project development, financing, energy strategy, and environmental commodities. Our team helps clients originate, structure, and execute opportunities in community solar, C&I, utility-scale, and renewable energy credit markets. Email us at info@reneuenergy.com to learn more.            

China EVs & More is back with a special Thanksgiving episode — and the China auto world did not take the week off.

233 - James Hunter (James Hunter Six) In episode 233 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with singer/guitarist and bandleader James Hunter, from the James Hunter Six. In their conversation James tells us about his home in Brighton, UK and what it's like to get around using the train and he tells us about the formation of his band the “James Hunter Six”. James talks about his style of music which is very mod ‘60's R&B. James describes his guitars a Gibson Les Paul Special a Gretsch 6120 and a Gretsch Electromatic Double Jet and he discusses his amps Vox AC30's. James discusses his musical education learning from his brother listening to Do Wop, Eddie Cochran and Gene Vincent playing pubs and bars in his neighborhood. James tells us about how he caught the ear of Van Morrison and how they ended up collaborating, one of the songs appearing on James Hunter's new album “Off the Fence”. James talks about his tour schedule and the difficulties of getting a visa to travel back to the USA where he used tour regularly before Covid. To find out more about James you can go to his website: jameshuntermusic.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #JamesHunterSix #JamesHunter #OfftheFence #VanMorrison #JamesPatrickRegan #GibsonGuitar #VoxAmps #GretschGuitars #theDeadlies #AC30 #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

Hey YC Online! Sermon notes: https://static1.squarespace.com/static/592f36b4d1758e4fdf70080e/t/692c8255f539d35a994c6c29/1764524629461/SG+11_29_25+ADVENT_+COMING+OF+THE+KING+OF+HEARTS+WEEK+1.pdf ABOUT YOSEMITE CHURCH: Our mission is meeting people where they are and loving them to where Christ wants them to be. Yosemite Church wants to help you find your next step. Find locations, videos, and more info about us at https://yc.church/ or download the Yosemite Church app. NEXT STEPS: Have you made a decision to follow Jesus? You may be wondering what's next on your journey. We want to help! Let us guide you to your next steps in your walk with Christ: https://yc.church/baptism GIVE ONLINE: https://pushpay.com/g/yosemitechurch FIND US ON SOCIAL MEDIA: https://www.facebook.com/yosemitechurch https://www.instagram.com/yosemitechurch/ All music performed under CCLI Licenses: 6010 and CSPL028666

Tales of Three Campaign OneArc 2.1 OladellEpisode 63: The Delegates Our Trio meets with two of the Seelie delegates and distributes water to the town. Content Warnings: Profanity, Reference to fantasy violence, romantic and sexual situations, and Water Scarcity. Tales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy! Follow the Cast:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Arianna⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠as Elara Spinelspark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dusty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as Ivy Nightbreeze- Tinkerfey  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wayra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as Véres Find our socials ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  Want to chat with the cast, talk spoilers, play games, and make new friends? Join our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  If you want to help keep the podcast running and get access to bonus content check out our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!Buy us a coffee on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ko-fi⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Special thanks to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SG ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the theme music, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chriss ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the logo, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fenn ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ely ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the character art! Background music and SFX by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Epidemic Sounds⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Monument Studios⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This week we're featuring our friends at Big Campaign podcast! Check out their podcast here!

Send us a textEver wondered why your referrals aren't pouring in despite your expertise? In this episode of the Serve First, Sell Later Marketing podcast, Sylvia Garibaldi, founder and CEO of SG and Associates, uncovers the surprising truth: it's all about trust, not skill. Learn why referrals hinge on making partners feel safe, discover the tiny signals that build or break trust, and get practical steps to skyrocket your referral network. Dive in to change your approach and consistently attract referrals with confidence!In this episode, you'll learn:  01:29 The Truth About Referrals02:54 Building Trust with Referral Partners06:05 Signals Referral Partners Notice09:36 Addressing Referral Partners' Fears13:31 Becoming the Go-To Professional18:02 Practical Steps to Increase Referrals Resources:Join us for the next webinar here.Feeling stuck about how to grow your practice, book a free strategy call here.#64 From Referral Plateau to Referral Powerhouse#77 Don't Sell Services. Sell the Feeling After.#88 5 Steps to Fast-Track Referral PartnershipsRate, Review, & Follow on Apple Podcasts"Love listening and learning from the Serve First, Sell Later Marketing Podcast” If that sounds like you, please consider rating and reviewing my show! This helps me support more people -- just like you. Click here, scroll to the bottom, tap to rate with five stars, and select “Write a Review.” Then be sure to let me know what you loved most about the episode! Want more insights like this? Sign up for our newsletter. Sign up for our free LinkedIn newsletter on marketing your professional practice Connect with me on linkedin Join our online community Subscribe to my youtube channel

SG1 helps Martin Lloyd reshape his movie script and sparks a storm of ridiculous rewrites—from sci-fi clichés to bold jabs at SG-1's own history. Jack Baruzzini, Jeff Haecker, Victor Lams, and special guest Fr. Cory Sticha unpack the wildest ideas. Is this the ultimate sci-fi roast? The post 200 (SG1) appeared first on StarQuest Media.

(토) 컬투쇼 - 사랑의 컬센타 (김태현 (딕펑스), 랄랄, 김용준 (SG워너비)) - 2025.11.8

Investor sentiment has dropped down to extreme fear as the financial headlines increasingly stoke concerns. Many stocks have dropped into bear territory but our analysts are decided to celebrate the "holiday" and give some of these bears a hug. The team also tackles Berkshire Hathaway's record pile of cash, Elon Musk's $1 trillion payday, and restaurant stocks before wrapping up with stocks on our radar. Jon Quast, Lou Whiteman and Emily Flippen discuss: - The fear and greed index is showing extreme fear. -Berkshire Hathaway is sitting on $382 billion. -Tesla approves Elon Musk's performance award that includes important operational milestones. -Denny's is being acquired, Papa John's bid is pulled, and Yum! Brands may be looking for a buyer for Pizza Hut. - Stocks on our radar. Companies discussed: BRK.A, BRK.B, TSLA, EATZ, DPZ, PZZA, YUM, CASY, SBUX, DENN, SG, DASH, AXON, LULU, IT, SMCI, CMG, DUOL, TTD, STN Host: Jon Quast Guests: Lou Whiteman, Emily Flippen Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Jimmy Hidalgo, Jr. is the favorite in Super Stock... but it's not over! Kris Whitfield is the favorite in SC... but it's not over! JJ Brock is the favorite in SG... but it's FAR from over! Luke does his best to break down all the scenarios (and even gives some odds) in today's Daily Driver!

4ª jornada de Champions: Liverpool 1 - 0 Real Madrid y Atlético 3 - 1 Unión SG. Protagonistas. Tiempo de opinión. Previa del La NFL, en Madrid. MundoMaldini.

As a young girl, mowing her neighbor's lawn in the Kentucky heat, SG Goodman learns many important things: how to avoid running into the chain-link fence, the art of blowing the grass away from the house ... and the way these small, regular acts of community become the glue holding the world together. In caring for Miss Betty across the street, and in caring for the land her father farms, SG learns to love the world and its stories, its songs, its connections that sustain us.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.